302964-06-3

Basic information

• Product Name: Carbamic acid, [5-[[(2-chloro-6-methylphenyl)amino]carbonyl]-2-thiazolyl]-, 1,1-dimethylethyl ester
• CAS NO: 302964-06-3
• Molecular Formula: C16H18ClN3O3S
• Molecular Weight: 367.856
• Mol File: 302964-06-3.mol

Chemical Properties

• CAS DataBase Reference: Carbamic acid, [5-[[(2-chloro-6-methylphenyl)amino]carbonyl]-2-thiazolyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [5-[[(2-chloro-6-methylphenyl)amino]carbonyl]-2-thiazolyl]-, 1,1-dimethylethyl ester(302964-06-3)
• EPA Substance Registry System: Carbamic acid, [5-[[(2-chloro-6-methylphenyl)amino]carbonyl]-2-thiazolyl]-, 1,1-dimethylethyl ester(302964-06-3)

Safety Data

• Hazardous Substances Data: 302964-06-3(Hazardous Substances Data)

Upstream product

• 79-37-8 oxalyl dichloride 
• 1101105-53-6 2-tert-butoxycarbonyloxyamino-thiazole-5-carboxylic acid chloride 
• 87-63-8 2-chloro-6-methylaniline 
• 302964-01-8 ethyl 2-[(tert-butoxycarbonyl)amino]-1.3-thiazole-5-carboxylate 
• 302964-02-9 2-[(tert-butoxycarbonyl)amino]-1,3-thiazole-5-carboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 302964-20-1 2-tert-butoxycarbonylamino-1,3-thiazole-5-carboxylic acid chloride 

Downstream Products

• 302964-24-5 2-amino-N-(2-chloro-6-methylphenyl)-1.3-thiazole-5-carboxamide 
• 302964-07-4 2-bromo-N-(2-chloro-6-methylphenyl)-1,3-thiazole-5-carboxamide 
• 302961-18-8 N-(2-chloro-6-methylphenyl)-2-[(2,6-dimethyl-4-pyrimidinyl)amino]-5-thiazolecarboxamide 

Relevant articles and documents

SUBSTITUTED ARYLUREA COMPOUNDS FOR INDUCING APOPTOSIS AND COMPOSITION FOR ANTICANCER COMPRISING THE SAME

The present invention relates to a substituted arylurea compound inducing apoptosis and an anticancer composition comprising the same. The present invention relates to a novel compound capable of preventing, treating and alleviating cancer diseases such as prostate cancer, breast cancer, lung cancer, colorectal cancer, and skin cancer by inhibiting apoptosis of cancer cells and inhibiting proliferation of cancer cells.

Protein kinase inhibitor and use thereof

The present invention provides a compound of formula 1 having an activity of inhibiting protein kinase and its use.

Scalable and impurity-free process for dasatinib: Src and BCR-Abl inhibitor

An efficient, telescopic, impurity-free and scalable process for Bcr-Abl and Src family tyrosine kinase inhibitor for synthesis of Dasatinib with high yield and purity is described.

AN IMPROVED PROCESS FOR THE PREPARATION OF DASATINIB POLYMORPH

The present invention is related to an improved process for the preparation of dasatinib anhydrous crystalline Neat form N-6 with high purity and high yield. The present invention also relates to purification of dasatinib crystalline Neat form N-6.

Dasatinib derivative with anti-tumor activity and application thereof

The invention belongs to the technical field of medicine chemistry and particularly relates to a dasatinib derivative with anti-tumor activity and application thereof. The dasatinib derivative provided by the invention has a very good inhibition effect on tyrosine kinase and has a very good application prospect for developing in the anti-tumor aspect.

A convenient new and efficient commercial synthetic route for dasatinib (Sprycel)

A new and efficient synthetic route for dual-Src/Abl kinase inhibitor dasatinib (Sprycel), an anticancer drug, is described. This commercially viable process yields dasatinib monohydrate free of potential impurities with consistent yield of 68% in route A and 61% in route B with HPLC purity >99.80% over four stages.

Method for preparing dasatinib intermediate

The invention relates to a simple, convenient, economical and efficient method for preparing a dasatinib intermediate [5-[[(2-chloro-6-methylphenyl)amino]carbonyl]-2-thiazolyl]tert-butyl carbamate, and provides a new synthesis and purification process. The yield is high, separation and purification are easy, and the method has great economic benefits and is suitable for industrial production.

EMS ANALOGUES OF LYN/SRC-TYROSINE KINASE INHIBITORS

Embodiments of the present invention are directed to compounds of the formula API―LG―ESM wherein "API" is a monovalent substituent group of an enzyme inhibitor; "LG" is a divalent substituent group of a linking group; and "ESM" is a monovalent substituent group of an esterase sensitive motif; or a pharmaceutically acceptable salt thereof. Other embodiments are directed to methods for using compounds of the formula API―LG―ESM to treat a number of medical conditions, including Alzheimer's disease.

PROCESS FOR THE PREPARATION OF DASATINIB AND ITS INTERMEDIATES

The present invention relates to processes for the preparation of dasatinib and its intermediates.

A new and efficient preparation of 2-aminothiazole-5-carbamides: Applications to the synthesis of the anti-cancer drug dasatinib

A new and efficient method has been developed for the synthesis of 2-amino-N-(-(2-chloro-6-methylphenyl)-thiazole-5-carboxamide. The new method involves a chemoselective α-bromination of β-ethoxyacrylamide followed by a one-pot treatment with thiourea to give the desired 2-aminothiazole-5-carboxylamide in excellent yield. Application of this new method to the efficient synthesis of the anti-cancer drug dasatinib was demonstrated.